1
|
Kumari S, Kuruvilla Thomas R, Sruthi S, Barani R, Sangvi S, Krishnamoorthy R, Srikanth P. Increased parvovirus B19 seropositivity in healthy blood donors in India. Sci Rep 2024; 14:20497. [PMID: 39227628 PMCID: PMC11372103 DOI: 10.1038/s41598-024-68095-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2023] [Accepted: 07/19/2024] [Indexed: 09/05/2024] Open
Abstract
A core component of every blood program is the supply of safe blood and blood products. The elevated risk of transmission through these products is due to parvovirus B19 (B19V) resistance to the virus inactivation procedures. Our study aimed to screen asymptomatic blood donors for B19V at a tertiary care hospital in Chennai, Tamil Nadu, between September 2020 and June 2021. Sera from 106 healthy blood donors who tested negative for Human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV), syphilis, and malaria were tested for anti-B19V IgM and IgG using a qualitative indirect enzyme-linked immunosorbent assay (ELISA). In the study population, 23.5% (n = 25) of donors tested IgM positive, 38.6% (n = 41) tested IgG positive, and 7.5% (n = 8) tested positive for both IgM and IgG. A proportion of 61.3% (n = 65) of the blood donors tested IgG negative, suggesting they had no past B19V infection. B19V DNA was not detected in any of the subjects. The high seroprevalence of IgM indicates that blood donors may have been recently exposed to B19V, potentially posing a risk to immunocompromised individuals and those with hematological stress. Further longitudinal studies with a larger sample size are recommended to better understand the risk of B19V transfusion transmission.
Collapse
Affiliation(s)
- Swati Kumari
- Department of Microbiology, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, 600116, Tamil Nadu, India
| | - Reuben Kuruvilla Thomas
- Department of Microbiology, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, 600116, Tamil Nadu, India
| | - S Sruthi
- Department of Microbiology, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, 600116, Tamil Nadu, India
| | - Ramya Barani
- Department of Microbiology, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, 600116, Tamil Nadu, India
| | - S Sangvi
- Department of Microbiology, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, 600116, Tamil Nadu, India
| | - R Krishnamoorthy
- Department of Transfusion Medicine, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India
| | - Padma Srikanth
- Department of Microbiology, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, 600116, Tamil Nadu, India.
| |
Collapse
|
2
|
Lu R, Xie S, Xu Z, Liu Z, Jiang J, Tang L, Jin Y, Fu X. Detection and analysis of parvovirus B19 among blood donors in a regional blood center in Eastern China. Heliyon 2024; 10:e35431. [PMID: 39166038 PMCID: PMC11334868 DOI: 10.1016/j.heliyon.2024.e35431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2024] [Revised: 07/21/2024] [Accepted: 07/29/2024] [Indexed: 08/22/2024] Open
Abstract
Background and objective The B19 virus is mainly transmitted through the respiratory tract; however, studies have shown that it can also be transmitted through blood transfusions or plasma products. This study investigated B19V antibodies, DNA, and gene typing in blood donors at a central blood station in China to evaluate the status of B19V infection. Materials and methods A total of 7728 samples from Suzhou Blood Center were collected from July 2022 to April 2023. Samples were detected for the B19V DNA using real-time polymerase chain reaction. Furthermore, 893 selected samples were screened for the seroprevalence of B19V antibodies using enzyme-linked immunosorbent assay. The NS1-VP1u fragment of the B19V DNA-positive samples was amplified using nested PCR, and the sequences were determined. A B19V phylogenetic tree was constructed using neighborhood joint and maximum parsimony methods to discriminate genotypes using the NS1-VP1u sequences. Results The percentages of IgG, IgM, and DNA were 19.4 %, 1.9 %, and 0.09 %, respectively. IgG positivity increased with age, and there was a significant difference among the blood groups. The IgG levels of repeat donors were greater than those of first-time donors. There were no apparent differences in the IgM levels in all the participants. Genotyping revealed that the B19 genotype was 1. Conclusions The prevalence of B19V antibodies and DNA was lower in these areas than in rest of China, indicating that the risk of B19V transmission via transfusion may be relatively low. However, during transfusion, particular attention should be paid to the B19V-susceptible populations, especially those in high-risk groups.
Collapse
Affiliation(s)
- Rong Lu
- Department of Blood Screening Test, Suzhou Blood Center, Suzhou, China
| | - Shuhong Xie
- Division of Transfusion Medicine, Suzhou Blood Center, Suzhou, China
| | - Zihao Xu
- Department of Blood Screening Test, Suzhou Blood Center, Suzhou, China
| | - Zhen Liu
- Department of Blood Screening Test, Suzhou Blood Center, Suzhou, China
| | - Jia Jiang
- Department of Blood Screening Test, Suzhou Blood Center, Suzhou, China
| | - Longhai Tang
- Transfusion Research Laboratory, Suzhou Blood Center, Suzhou, China
| | - Yiming Jin
- Department of Blood Screening Test, Suzhou Blood Center, Suzhou, China
| | - Xiaoyan Fu
- Department of Blood Screening Test, Tai Cang Blood Branch Station, Tai Cang, China
| |
Collapse
|
3
|
Kumari S, Thomas RK, R K, Barani R, Srikanth P. Ensuring Transfusion Safety: Screening Blood Donors for Human Parvovirus B19. Cureus 2024; 16:e67359. [PMID: 39310657 PMCID: PMC11413613 DOI: 10.7759/cureus.67359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/20/2024] [Indexed: 09/25/2024] Open
Abstract
Ensuring the safety of blood and blood products is a vital aspect of healthcare. The potential for transmission of pathogens through blood and blood products makes transfusion safety a significant concern. Despite advancements in testing methodologies, donated blood products still pose a risk for infection transmission. Human parvovirus B19 (B19V) is a small, single-stranded, non-enveloped DNA virus transmissible parenterally by blood transfusion. B19V causes a wide range of clinical manifestations, which is generally harmless in healthy individuals. B19V infection may cause severe complications, such as aplastic crises, as it affects erythrocyte progenitor cells in individuals with increased erythrocyte turnover. Additionally, B19V can be transmitted from pregnant women to their foetus, potentially causing hydrops fetalis and foetal death. The potential for transmission through blood and blood products makes B19V a significant concern for transfusion safety. In response to the growing recognition of B19V's impact on transfusion safety, various international health organisations have introduced guidelines to minimise its transmission through blood and plasma products. However, the implementation of these guidelines varies globally, with some regions, such as India, still lacking formal protocols for B19V monitoring. This review article explores the existing methodologies for screening blood donors for B19V, assesses the associated transfusion risks, and considers the implications for public health and clinical practice. By emphasising advancements in diagnostic techniques and the challenges of their implementation, this article provides a comprehensive overview of efforts to reduce the transmission of B19V through blood transfusions, thereby ensuring safer blood supplies and improved patient outcomes.
Collapse
Affiliation(s)
- Swati Kumari
- Microbiology, Sri Ramachandra Institute of Higher Education and Research, Chennai, IND
| | | | - Krishanamoorthy R
- Transfusion Medicine, Sri Ramachandra Institute of Higher Education and Research, Chennai, IND
| | - Ramya Barani
- Microbiology, Sri Ramachandra Institute of Higher Education and Research, Chennai, IND
| | - Padma Srikanth
- Microbiology, Sri Ramachandra Institute of Higher Education and Research, Chennai, IND
| |
Collapse
|
4
|
De Paschale M, Pavia C, Cerulli T, Cagnin D, Manco MT, Belvisi L, Paganini A, Pogliani L, Ceriani E, Porta A, Parola L, Mirri P, Osnaghi B, Vismara L, Clerici P. Prevalence of anti-parvovirus B19 IgG and IgM and parvovirus B19 viremia in pregnant women in an urban area of Northern Italy. J Med Virol 2022; 94:5409-5414. [PMID: 35764590 DOI: 10.1002/jmv.27963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 06/22/2022] [Accepted: 06/25/2022] [Indexed: 12/15/2022]
Abstract
Parvovirus B19 (B19V) infection in pregnancy is mostly asymptomatic, but can cause complications including abortion and fetal hydrops. Although its infection is ubiquitous, seroprevalence among pregnant women varies according to different geographical areas. Since seroprevalence data in Italy are limited, the prevalence of antibodies and DNA in pregnant women was evaluated retrospectively, correlating the clinical situation of mothers and newborns. One thousand eight hundred and ninety-three sequential sera were examined from pregnant women (60.8% in the first trimester, 16.6% in the second one, and 22.6% in the third one, respectively) for anti-B19V IgG and IgM (confirmed by immunoblot); 1402 (74.1%) were of Italian origin and 491 (25.9%) non-Italian women. Molecular tests were used to search for viral genome. One thousand three hundred and fifteen (69.5%) samples were IgG-positive, 21 (1.1%) IgM-positive, and 578 (30.5%) nonimmune. The difference in IgG seroprevalence between Italian (71.1%) and non-Italian women (64.8%) was statistically significant. Of the 21 IgM-positive women, 16 were confirmed positive also by immunoblot (prevalence: 0.8%), of which 11 were viraemic (prevalence: 0.6%; mean 1.3 × 104 geq/ml). Mothers were asymptomatic, and the newborns had no clinical signs of congenital infection. IgG seroprevalence in Italy is high, with differences between Italian women and non-Italian women from geographic areas with lower endemic levels of B19V. The consistent migratory flows in place could lead to an increase in the number of susceptible women. The prevalence of viremia is low, and has not been associated with evident fetal damage at birth.
Collapse
Affiliation(s)
| | - Claudia Pavia
- Microbiology Unit, Hospital of Legnano, ASST Ovest Milanese, Milan, Italy
| | - Teresa Cerulli
- Microbiology Unit, Hospital of Legnano, ASST Ovest Milanese, Milan, Italy
| | - Debora Cagnin
- Microbiology Unit, Hospital of Legnano, ASST Ovest Milanese, Milan, Italy
| | - Maria T Manco
- Microbiology Unit, Hospital of Legnano, ASST Ovest Milanese, Milan, Italy
| | - Luisa Belvisi
- Microbiology Unit, Hospital of Legnano, ASST Ovest Milanese, Milan, Italy
| | - Alessia Paganini
- Microbiology Unit, Hospital of Legnano, ASST Ovest Milanese, Milan, Italy
| | - Laura Pogliani
- Pediatric Unit, Hospital of Legnano, ASST Ovest Milanese, Milan, Italy
| | - Elena Ceriani
- Pediatric Unit, Hospital of Legnano, ASST Ovest Milanese, Milan, Italy
| | - Alessandro Porta
- Pediatric Unit, Hospital of Magenta, ASST Ovest Milanese, Milan, Italy
| | - Luciana Parola
- Pediatric Unit, Hospital of Magenta, ASST Ovest Milanese, Milan, Italy
| | - Paola Mirri
- Microbiology Unit, Hospital of Legnano, ASST Ovest Milanese, Milan, Italy
| | - Bianca Osnaghi
- Microbiology Unit, Hospital of Legnano, ASST Ovest Milanese, Milan, Italy
| | - Laura Vismara
- Microbiology Unit, Hospital of Legnano, ASST Ovest Milanese, Milan, Italy
| | - Pierangelo Clerici
- Microbiology Unit, Hospital of Legnano, ASST Ovest Milanese, Milan, Italy
| |
Collapse
|
5
|
Pattabiraman C, Prasad P, Sudarshan S, George AK, Sreenivas D, Rasheed R, Ghosh A, Pal A, Hameed SKS, Bandyopadhyay B, Desai A, Vasanthapuram R. Identification and Genomic Characterization of Parvovirus B19V Genotype 3 Viruses from Cases of Meningoencephalitis in West Bengal, India. Microbiol Spectr 2022; 10:e0225121. [PMID: 35412386 PMCID: PMC9045363 DOI: 10.1128/spectrum.02251-21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Accepted: 03/19/2022] [Indexed: 12/03/2022] Open
Abstract
Brain infections are a major public health problem in India and other parts of the world, causing both mortality and lifelong disability. Even after a thorough investigation, many cases remain without an etiological diagnosis. Primate erythroparvovirus 1 (B19V) has been identified as a pathogen associated with undiagnosed meningoencephalitis in other settings, including the United Kingdom, France, and Latvia. Here, we reported 13/403 (3.2%) B19V PCR positive cases of meningoencephalitis in West Bengal, India. The positive samples were mostly from children (10/13, 76.92%) and presented as a spectrum consisting of acute encephalitis (7/13), acute meningoencephalitis (3/13), and meningitis (3/13). Of the 13 cases, 8/13 (61.5%) had no known etiology and 5/13 (38.5%) had a previous etiological diagnosis. The cases did not cluster in time or by location, suggesting sporadic occurrence rather than outbreaks. We were able to retrieve the complete B19V genomes from cerebrospinal fluid (CSF) in 12/13 cases. The sequences clustered into genotype 3b with complete genomes from Brazil, Ghana, and France, and partial genomes from India and Kyrgyzstan. This is the first report of B19V in cases of neurological infections from India. It highlights the need to evaluate the causal relationship between B19V with meningoencephalitis in the country. These were also the first complete genomes of genotype 3b from CSF and will be critical in the evaluation of the relationship between genotypes and disease. IMPORTANCE Cases of meningoencephalitis with no known etiology remain a major challenge to clinical management of brain infections across the world. In this study, we detected and characterized the whole-genome of primate erythroparvovirus 1 (B19V) in cases of meningoencephalitis in India. Our work highlighted the association between B19V and brain infections which has been reported in other countries. Our work also emphasized the need to examine the role of B19V in meningoencephalitis, specifically whether it caused or contributed to the disease together with other pathogens in India. Our study provided the first 12 genomes of B19V from cerebrospinal fluid. These genomes will contribute to an understanding of how the virus is changing across different locations and over time.
Collapse
Affiliation(s)
- Chitra Pattabiraman
- Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bengaluru, India
| | - Pramada Prasad
- Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bengaluru, India
| | - Sampada Sudarshan
- Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bengaluru, India
| | - Anson K. George
- Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bengaluru, India
| | - Darshan Sreenivas
- Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bengaluru, India
| | - Risha Rasheed
- Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bengaluru, India
| | - Ayushman Ghosh
- Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bengaluru, India
| | - Ananya Pal
- Department of Microbiology, Calcutta School of Tropical Medicine, Kolkata, India
| | - Shafeeq K. Shahul Hameed
- Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bengaluru, India
| | - Bhaswati Bandyopadhyay
- Virology Unit, Department of Microbiology, Calcutta School of Tropical Medicine, Kolkata, India
| | - Anita Desai
- Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bengaluru, India
| | - Ravi Vasanthapuram
- Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bengaluru, India
| |
Collapse
|
6
|
Farahmand M, Tavakoli A, Ghorbani S, Monavari SH, Kiani SJ, Minaeian S. Molecular and serological markers of human parvovirus B19 infection in blood donors: A systematic review and meta-analysis. Asian J Transfus Sci 2021; 15:212-222. [PMID: 34908757 PMCID: PMC8628227 DOI: 10.4103/ajts.ajts_185_20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Accepted: 05/16/2021] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND: Human parvovirus B19 (B19V) is one of the blood-borne viruses. The virus can be transmitted to susceptible individuals by blood or blood products. The virus is not associated with significant disease in general population, while people with underlying problems such as immunodeficiency can cause anemia and arthritis. The current systematic review and meta-analysis aimed to estimate the overall prevalence of B19V DNA, anti-B19V IgG, and anti-B19V IgM antibodies in blood donors worldwide. METHODS: A systematic search was carried out in online databases for relevant studies from inception until March 30, 2019. Study selection was performed based on predesigned eligibility criteria. The proportion of B19V DNA, anti-B19V IgG, and anti-B19V IgM antibodies were pooled using the inverse variance method. All statistical analyses were performed using the R version 3.5.3, package “meta.” RESULTS: According to the random-effects model, the pool prevalence of B19V DNA, anti-B19V IgM, and anti-B19V IgG among blood donors was calculated to be 0.4% (95% confidence interval [CI] =0.3%–0.6%), 2.2% (95% CI = 1.3%–3.7%), and 50.1% (95% CI = 43.1%–57.1%), respectively. CONCLUSION: For the transmission of B19V through blood, the presence of the virus genome is required, and the present study showed that the prevalence of the virus genome in blood donors is <1%. Therefore, there is no need to screen donated blood for B19V infection.
Collapse
Affiliation(s)
- Mohammad Farahmand
- Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| | - Ahmad Tavakoli
- Department of Medical Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.,Research Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran
| | - Saied Ghorbani
- Department of Medical Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Seyed Hamidreza Monavari
- Department of Medical Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Seyed Jalal Kiani
- Department of Medical Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Sara Minaeian
- Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
7
|
Beyond Cytomegalovirus and Epstein-Barr Virus: a Review of Viruses Composing the Blood Virome of Solid Organ Transplant and Hematopoietic Stem Cell Transplant Recipients. Clin Microbiol Rev 2020; 33:33/4/e00027-20. [PMID: 32847820 DOI: 10.1128/cmr.00027-20] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Viral primary infections and reactivations are common complications in patients after solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT) and are associated with high morbidity and mortality. Among these patients, viral infections are frequently associated with viremia. Beyond the usual well-known viruses that are part of the routine clinical management of transplant recipients, numerous other viral signatures or genomes can be identified in the blood of these patients. The identification of novel viral species and variants by metagenomic next-generation sequencing has opened up a new field of investigation and new paradigms. Thus, there is a need to thoroughly describe the state of knowledge in this field with a review of all viral infections that should be scrutinized in high-risk populations. Here, we review the eukaryotic DNA and RNA viruses identified in blood, plasma, or serum samples of pediatric and adult SOT/HSCT recipients and the prevalence of their detection, with a particular focus on recently identified viruses and those for which their potential association with disease remains to be investigated, such as members of the Polyomaviridae, Anelloviridae, Flaviviridae, and Astroviridae families. Current knowledge of the clinical significance of these viral infections with associated viremia among transplant recipients is also discussed. To ensure a comprehensive description in these two populations, individuals described as healthy (mostly blood donors) are considered for comparative purposes. The list of viruses that should be on the clinicians' radar is certainly incomplete and will expand, but the challenge is to identify those of possible clinical significance.
Collapse
|
8
|
van Hoeven LR, Janssen MP, Lieshout-Krikke RW, Molenaar-de Backer MW. An assessment of the risk, cost-effectiveness, and perceived benefits of anti-parvovirus B19 tested blood products. Transfusion 2019; 59:2352-2360. [PMID: 31032994 DOI: 10.1111/trf.15324] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Revised: 02/14/2019] [Accepted: 03/03/2019] [Indexed: 01/07/2023]
Abstract
BACKGROUND Parvovirus B19 (B19V) can cause severe anemia, hydrops foetalis, and even death in vulnerable patients. To prevent transfusion-transmitted B19V infection of at-risk patients, B19V antibody screening of blood donors was implemented. The cost-effectiveness of this intervention is unclear, as the likelihood of transmission through blood and subsequent complications for recipients are unknown. This study estimates the cost-effectiveness of anti-B19V donor screening in the Netherlands. STUDY DESIGN AND METHODS The estimates needed for the cost-effectiveness model were: the occurrence of B19V in Dutch blood donors, the number of anti-B19V tested products required by hospitals, the likelihood of morbidity and mortality given B19V infection, treatment costs, and screening costs. These estimates were obtained from literature and observational data. When data were unavailable, structured expert judgment elicitation and statistical modeling were applied. RESULTS The costs of preventing one transfusion transmitted B19V infection are estimated at €68,942 (€42,045 - €102,080). On average, 1.25 cases of morbidity and 0.12 cases of mortality are prevented annually. Although the perceived risk of transfusion transmitted B19V infection was low, half of the treating physicians favored anti-B19V screening. CONCLUSION The estimated mortality and morbidity caused by B19V infection was low in the risk groups. The cost-effectiveness ratio is similar to other blood safety screening measures. No guidance exists to evaluate the acceptability of this ratio. The explicit overview of costs and effects may further guide the discussion of the desirability of B19V safe blood products.
Collapse
Affiliation(s)
- Loan R van Hoeven
- Donor Medicine Research Transfusion Technology Assessment Department, Sanquin Research, Amsterdam, The Netherlands
| | - Mart P Janssen
- Donor Medicine Research Transfusion Technology Assessment Department, Sanquin Research, Amsterdam, The Netherlands
| | | | | |
Collapse
|
9
|
Das P, Chatterjee K, Chattopadhyay NR, Choudhuri T. Evolutionary aspects of Parvovirus B-19V associated diseases and their pathogenesis patterns with an emphasis on vaccine development. Virusdisease 2019; 30:32-42. [PMID: 31143830 PMCID: PMC6517593 DOI: 10.1007/s13337-019-00525-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Accepted: 03/15/2019] [Indexed: 12/16/2022] Open
Abstract
Parvovirus B-19, a single human pathogenic member of the Parvoviridae family with it's small ssDNA and non-enveloped structure, is known to cause diseases in erythroid progenitor cells. But a wide range of clinical association of this virus with cells of non-erythroid origins has recently been discovered and many of those are being investigated for such association. Higher substitution rates in due course of evolution has been suggested for this cellular tropism and persistence. In this report, we have summarized the different disease manifestations of B-19 virus and have tried to find out a pattern of pathogenesis. Finally, we have focused on the vaccination strategies available against B-19 virus to correlate these with the mechanisms involved in various diseases caused by this virus.
Collapse
Affiliation(s)
- Piyanki Das
- Department of Biotechnology, Visva Bharati Santiniketan, Siksha Bhavana, Bolpur, West Bengal 731235 India
| | - Koustav Chatterjee
- Department of Biotechnology, Visva Bharati Santiniketan, Siksha Bhavana, Bolpur, West Bengal 731235 India
| | - Nabanita Roy Chattopadhyay
- Department of Biotechnology, Visva Bharati Santiniketan, Siksha Bhavana, Bolpur, West Bengal 731235 India
| | - Tathagata Choudhuri
- Department of Biotechnology, Visva Bharati Santiniketan, Siksha Bhavana, Bolpur, West Bengal 731235 India
| |
Collapse
|